The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive.
All News
Article
Article
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Article
Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery. We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.
Article
Previously quoted average delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years.
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/VvKZaeVumy https://t.co/1shpS0Ajn4
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?
https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/W6kjahdLEu https://t.co/QyTmlhb235
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain
An interesting read from @CreakyJoints. Check it out our synopsis.
https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h
Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!
Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/5tomZsaaU6 https://t.co/yAMGY5nlCU
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/b9pX9NgZAx https://t.co/RL9vi3Xbf6
Prospective randomized trial of ultrasound-guided genicular nerve block (GNB) vs physical therapy (PT) i102 pts chronic knee #OA - GNB was superior at walk distance, pain, functional and physical capacity, at 12 weeks https://t.co/MOJ16zAiqH https://t.co/JJJye2dobH
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances.
This webinar will feature highlights from:
PsA Guidelines
Arthur Kavanaugh, MD
Drug Targeting in PsA
Bruce Kirkham, MD
PsA Registries and Real World Data
Alexis Ogdie, MD
https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease
A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD.
https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun


